Procept's Aquablation BPH Therapy Gets Boost From UK NICE Guidance
The UK's NICE issued a recommendation approving Procept's AquaBeam Aquablation therapy as an alternative to surgical treatments for benign prostate hyperplasia just as a Medciare new technology add-on payment takes effect for Aquablation in the US.
You may also be interested in...
Results Recap: EndoBarrier Improves Obesity And Diabetes Outcomes In UK Study; Procept’s Aquablation Proves Effective Again
Medtech Insight's Results Recap covers major device trial results appearing on MedDeviceTracker. This week's edition covers new clinical data released March 8 to March 22, not including the data presented at the annual conferences of the American Academy of Orthopedic Surgeons or American College of Cardiology, which are presented in separate special editions of Results Recap.
The US Medicare agency granted inpatient new-technology add-on payments for Boston Scientific's newly acquired cerebral protection system for TAVR, Respicardia's neurostimulator for sleep apnea and Procept BioRobotics' novel resection system for benign prostatic hyperplasia. The highly selective bonus payments typically help drive adoption for the chosen new technologies.
Results of the WATER II trial confirm that Aquablation is a safe and effective treatment of benign prostate hyperplasia for large prostates, and manufacturer Procept BioRobotics is confident the procedure will eventually displace all other prostate resection techniques because it is easy for surgeons to learn.